Phrontline Biopharma
Shanghai
About Phrontline Biopharma
Phrontline Biopharma develops biopharmaceutical products to treat cancer through innovative antibody-drug conjugate technology. The company's innovation lies in engineering bispecific antibodies combined with a dual-payload platform, enabling simultaneous delivery of two cytotoxic agents. Its lead program, TJ101, is a bispecific ADC directed at EGFR and B7-H3 for solid tumors; it has received IND clearance and has entered a Phase 1 clinical trial. Other pipeline assets (like TJ102, TJ106, TJ108, TJ109, and TJ111) target combinations such as FR╬▒/CDH6, HER2/HER2, EGFR/HER3, EGFR/MET, and Trop2/Nectin4, covering cancer types like ovarian, breast, urothelial, and non-small cell lung cancer. Their proprietary SynTume 2×2 technology underlies this work, offering a modular design for ADC construction.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $73.8M
- Funding stage: Seed
- Last round: Seed (Nov 2025)
- Website: phrontlinebio.com
- Phone: +86 21 50476277
Industries & Categories
Biopharma, Manufacturing, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/phrontline-biopharma-51149 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.